Pharmaceuticals · PH-05 · Plant warehouse: quarantine, release and raw materials
Unreleased raw materials must not reach the production line.
Pharmaceutical production grew by 29.4% in January–May 2026; the 2026 target is UZS 8.5 trillion. As volumes grow, a core GMP requirement is that the quarantine, released and rejected statuses of raw materials and finished products are held in the warehouse system.
Platform: Plant Pulse, Goods Flow
Who it is for
- Warehouse
- Receipt and issue.
- QC
- Testing and release.
- QA
- Status control.
- Production
- Material withdrawal.
Where the problem lies
Manual labels
Quarantine and release labels are changed by hand.
Sampling
Samples taken for QC are not deducted from stock.
Issue
Release status is not checked for material issued to the line.
Finished product
A batch not released by QA can end up in a shipment.
How the loss is calculated
| Rejected batch | batch value (UZS) |
|---|---|
| Deviation investigation | QA hours × QA hourly cost (UZS/hour) |
| Stock discrepancy | discrepancy quantity (units) × unit price (UZS/unit) |
| Inspection | number of observations |
Calculate with your data
QA labour cost of GMP deviation investigations: current state vs. your scenario
This calculator estimates the monthly QA labour cost of investigating deviations caused by GMP status errors (quarantine/release) and picking errors in the plant warehouse.
Use spaces for thousands and a dot or comma for decimals. Use the same currency throughout.
Values stay in this page and are not sent to the server.
Scenario estimate
0 / 5 values entered
Enter your operating figures to see the estimate.
Only the QA labour spent on deviation investigations is covered, for a one-month period. The value of rejected batches, stock discrepancies, inspection observations, production downtime and penalties are excluded and are not added in. The scenario deviation count and hours are your own assumptions and are not guaranteed to be achievable. The calculation does not confirm GMP/GDP compliance, an inspection outcome or validation status. Firm timelines and prices can only be given after an audit and measurement.
Formulas and assumptions
This calculator estimates the monthly QA labour cost of investigating deviations caused by GMP status errors (quarantine/release) and picking errors in the plant warehouse. Take the number of investigated deviations from WMS, scanner (TSD) data or the deviation log, and enter the hours and QA hourly cost from your own records. All results are estimates only.
- Current state: QA cost of deviation investigations
- Deviations per month (cases/month) × person-hours per deviation × QA hourly cost (currency/hour) = monthly QA labour cost (currency/month).
- Scenario: QA cost of deviation investigations
- Scenario deviations per month (cases/month) × scenario person-hours per deviation × QA hourly cost (currency/hour). This reflects your assumption, not a guarantee.
- Difference between current state and scenario (estimate)
- Current monthly QA cost (currency/month) minus scenario monthly QA cost (currency/month). If the scenario cost is higher, the result is shown as 0. This is an estimated difference in QA labour, not a guaranteed saving.
Facts and global practice
National Statistics Committee
In January–May 2026, pharmaceutical production exceeded UZS 2.3 trillion, +29.4%.1
yuz.uz
2026 target: production of UZS 8.5 trillion, $800 million in projects.2
Presidential meeting
Over nine years, $1.8 billion has been invested in the sector and 140 new production capacities commissioned.3
When new capacities come online, warehouse processes often stay the old way.
Every batch has a status
The warehouse system maintains quarantine, released, rejected and sample statuses, and enforces a status check when materials are issued to the line and when goods are shipped.
- 01Receipt
- Batch
- Quarantine
- Sample
- 02QC
- Testing
- Release
- Reject
- 03Issue
- Line
- Check
- Stock
- 04Finished
- QA release
- Warehouse
- Shipment
Modules
The current maturity level is shown next to each module.
| WMS: GMP statuses | Quarantine, release, reject | Commercially available |
|---|---|---|
| Link to QC | Test result | Engineering capability |
| Line issue control | Scanner | Commercially available |
| 1C integration | Stock | Commercially available |
How we start
- 01
Warehouse audit
Statuses and process.
Outcome: gaps.
- 02
Pilot
Raw material warehouse.
Outcome: statuses in the system.
- 03
Expansion
Finished product.
Outcome: full coverage.
- 04
Subscription
Monthly.
Outcome: trend.
What is measured
| Status errors | Cases | WMS |
|---|---|---|
| Test waiting time | Days | System |
| Stock accuracy | Discrepancy | WMS |
| Issue errors | Cases | Handheld terminal |
What is needed to start
- Warehouse manager
- Head of QC
- Batch procedure
- Test access to 1C
What we do not promise
- Exact timeline and price without an audit
- GMP/GDP certification or inspection outcome
- Approving validation documents ourselves
- Unmeasured results
Self-check
- Is quarantine status maintained in the system?
- Is QC release transferred to the system automatically?
- Is the status checked when material is issued to the line?
- Are samples deducted from stock?
- Are batches not released by QA blocked?
- Are rejected batches stored in a separate location?
- Are labels printed from the system?
- Does stock match 1C?
- Can status history be shown during an inspection?
- Is a responsible person assigned?
Plant warehouse audit
We review raw material and finished product statuses.
- Map of breakpoints
- Pilot plan
- Implementation fee and monthly subscription
Other solutions in this industry
- PH-01GDP warehouse: temperature and batch data in one system
- PH-02Shelf life and FEFO
- PH-03Warehouse operations with marking codes
- PH-04Moving to EU GMP: the electronic batch record
- PH-06Compliance with reference prices
- PH-07Reimbursement: prescription, code, receipt and ESF
- PH-08Quality control laboratory and data integrity
- PH-09Imported medicines warehouse and customs requirements
- PH-10Packaging line productivity
Sources
- National Statistics Committee: pharmaceutical production, January–May 2026. kun.uz, 16.07.2026.
- Decree of 05.03.2026 on stimulating the pharmaceutical sector: 2026 targets. yuz.uz, 2026.
- Presidential videoconference: expanding production in the pharmaceutical industry. president.uz, 05.03.2026.